These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20427120)

  • 1. Re: Noel W. Clarke, Michael Marberger. The motion: GnRH antagonists are the new way forward in hormonal therapy. Eur Urol 2010;57:534-7.
    Drewa TA; Chlosta PL
    Eur Urol; 2010 Aug; 58(2):e20. PubMed ID: 20427120
    [No Abstract]   [Full Text] [Related]  

  • 2. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
    van Poppel H; Nilsson S
    Urology; 2008 Jun; 71(6):1001-6. PubMed ID: 18407326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84.
    Weston P; Persson BE
    Eur Urol; 2005 Mar; 47(3):422; author reply 422. PubMed ID: 15716212
    [No Abstract]   [Full Text] [Related]  

  • 4. Open to debate. The motion: GnRH antagonists are the new way forward in hormonal therapy.
    Clarke NW; Marberger M
    Eur Urol; 2010 Mar; 57(3):534-7. PubMed ID: 20015590
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 6. Incomplete testosterone suppression in prostate cancer.
    Crawford ED; Rove KO
    N Engl J Med; 2010 Nov; 363(20):1976. PubMed ID: 21067409
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.
    Djavan B; Schlegel P; Salomon G; Eckersberger E; Sadri H; Graefen M
    Can J Urol; 2010 Aug; 17(4):5265-71. PubMed ID: 20735905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of cancer of the prostate. New hormonal approaches].
    Schaison G
    Pathol Biol (Paris); 1989 Feb; 37(2):118-9. PubMed ID: 2523530
    [No Abstract]   [Full Text] [Related]  

  • 10. GnRH antagonists in the treatment of advanced prostate cancer.
    Pommerville PJ; de Boer JG
    Can J Urol; 2010 Apr; 17(2):5063-70. PubMed ID: 20398443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Pickles T
    J Urol; 2005 Dec; 174(6):2423-4; author reply 2424. PubMed ID: 16280866
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
    Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New possibilities in the hormonal therapy of metastatic carcinoma of the prostate].
    Cicin-Sain D; Pasini J
    Lijec Vjesn; 1989 Nov; 111(11):405-7. PubMed ID: 2699907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of advanced prostate cancer: gonadotropin-releasing hormone blockers might improve prognosis.
    Heidenreich A
    Eur Urol; 2008 Oct; 54(4):726-7. PubMed ID: 18524468
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Greil et al.: Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals (Urology 2009;73:631-634).
    Tan WW
    Urology; 2009 Jun; 73(6):1427-8. PubMed ID: 19482168
    [No Abstract]   [Full Text] [Related]  

  • 17. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L; Iversen P; Persson BE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal treatment of prostate cancer.
    Garnick MB
    N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
    Sharma R; Sundar S
    Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM; Chertin B; Lindenberg T; Farkas A
    N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.